MHRA
- Local brand name: Xolremdi
- Status: approved
Xolremdi (MAVORIXAFOR) regulatory status in United Kingdom.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MHRA has authorised it.
X4 Pharms is the originator. The local marketing authorisation holder may differ — check the official source linked above.